Pretzel buys Rome and its ‘dark genome’ worknews2026-01-12T21:37:31+00:00January 12th, 2026|Endpoints News|
Arkin Capital raises $100M to back a dozen early-stage biotechsnews2026-01-12T13:00:45+00:00January 12th, 2026|Endpoints News|
Kinaset rakes in $103M to advance inhaled asthma drugnews2026-01-12T11:49:32+00:00January 12th, 2026|Endpoints News|
Private and public biotechs go on $4.9B funding spree ahead of JPMnews2026-01-11T14:00:31+00:00January 11th, 2026|Endpoints News|
Hair growth biotech Veradermics files for IPO to fund oral Rogainenews2026-01-10T18:07:44+00:00January 10th, 2026|Endpoints News|
Aktis’ 25% IPO bounce builds hope for 2026’s public offeringsnews2026-01-09T18:44:41+00:00January 9th, 2026|Endpoints News|
BioNTech, UPenn team up for $50M seed fundnews2026-01-09T16:25:30+00:00January 9th, 2026|Endpoints News|
Gene editing pioneers launch first startup focused on custom CRISPR therapiesnews2026-01-09T11:00:27+00:00January 9th, 2026|Endpoints News|
Aktis lands biotech’s first IPO of 2026, raising $318M for radiopharmaceuticalsnews2026-01-09T02:42:48+00:00January 9th, 2026|Endpoints News|
Secretive Rampart Bioscience closes after pursuing non-viral gene therapynews2026-01-08T17:59:21+00:00January 8th, 2026|Endpoints News|
